Roni Mamluk
Direttore/Membro del Consiglio presso AMRYT PHARMA PLC
Profilo
Roni Mamluk is a professional with experience in various firms.
Currently, she is working as a Non-Executive Director at Amryt Pharma Plc and also as a Venture Advisor at Israel Biotech Fund.
Previously, she worked as the President, Chief Executive Officer & Director at Old Ayala, Inc. from 2017 to 2023.
She also worked as an Independent Director at Chiasma, Inc. from 2006 to 2021 and as a Director at Chiasma (Israel) Ltd.
from 2015 to 2021.
Additionally, she served as a Non-Executive Director at Amryt Pharma Holdings Ltd.
and as the Head-Non Clinical Research & Development at Adnexus.
Dr. Mamluk holds an undergraduate and doctorate degree from The Hebrew University of Jerusalem and a graduate degree from Harvard Medical School.
Posizioni attive di Roni Mamluk
Società | Posizione | Inizio |
---|---|---|
AMRYT PHARMA PLC | Direttore/Membro del Consiglio | 05/08/2021 |
Israel Biotech Fund
Israel Biotech Fund Investment ManagersFinance Israel Biotech Fund (Israel Biotech) is a venture capital firm founded in 2015 by Yuval Cabilly, David Sidransky, and Gidon Zairi. The firm is headquartered in Rehovot, Israel. | Consulente / Consigliere | - |
Precedenti posizioni note di Roni Mamluk
Società | Posizione | Fine |
---|---|---|
ADVAXIS, INC. | Amministratore Delegato | 19/01/2023 |
Chiasma (Israel) Ltd. | Direttore/Membro del Consiglio | 01/08/2021 |
CHIASMA, INC. | Amministratore Delegato | 17/06/2015 |
Amryt Pharma Holdings Ltd.
Amryt Pharma Holdings Ltd. Pharmaceuticals: MajorHealth Technology Amryt Pharma Holdings Ltd. is a pharmaceutical company, which engages in the development and delivery of treatments to help improve the lives of patients with rare and orphan diseases. Its products include Lomitapide and Metreleptin. The Lomitapide provides homozygous familial hypercholesterolemia (HoFH), and Metreleptin provides treatment for generalized lipodystrophy (GL) and partial lipodystrophy (PL). The company was founded on December 20, 2004 and is headquartered in London, the United Kingdom. | Direttore/Membro del Consiglio | - |
Adnexus
Adnexus Pharmaceuticals: MajorHealth Technology Adnexus engages in the development of Adnectins biologics and medicines in the United States. The company was founded by Frank D. Lee on September 16, 2002 and is headquartered in Waltham, MA. | Corporate Officer/Principal | - |
Formazione di Roni Mamluk
The Hebrew University of Jerusalem | Doctorate Degree |
Harvard Medical School | Graduate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
Aziende private | 7 |
---|---|
Chiasma, Inc.
Chiasma, Inc. Pharmaceuticals: MajorHealth Technology Chiasma, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of oral forms of therapies that are available by injection. Its products include octreotide capsules. The company was founded by Shmuel A. Ben-Sasson and Guy Yachin in 2001 and is headquartered in Needham, MA. | Health Technology |
Adnexus
Adnexus Pharmaceuticals: MajorHealth Technology Adnexus engages in the development of Adnectins biologics and medicines in the United States. The company was founded by Frank D. Lee on September 16, 2002 and is headquartered in Waltham, MA. | Health Technology |
Chiasma (Israel) Ltd. | |
Israel Biotech Fund
Israel Biotech Fund Investment ManagersFinance Israel Biotech Fund (Israel Biotech) is a venture capital firm founded in 2015 by Yuval Cabilly, David Sidransky, and Gidon Zairi. The firm is headquartered in Rehovot, Israel. | Finance |
Amryt Pharma Holdings Ltd.
Amryt Pharma Holdings Ltd. Pharmaceuticals: MajorHealth Technology Amryt Pharma Holdings Ltd. is a pharmaceutical company, which engages in the development and delivery of treatments to help improve the lives of patients with rare and orphan diseases. Its products include Lomitapide and Metreleptin. The Lomitapide provides homozygous familial hypercholesterolemia (HoFH), and Metreleptin provides treatment for generalized lipodystrophy (GL) and partial lipodystrophy (PL). The company was founded on December 20, 2004 and is headquartered in London, the United Kingdom. | Health Technology |
Old Ayala, Inc.
Old Ayala, Inc. Pharmaceuticals: MajorHealth Technology Old Ayala, Inc. operates as a clinical-stage oncology company. It focuses on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers. It also involved in in precision oncology, targeted therapy, drug development, companion diagnostics, and biomarkers. The company was founded in November 2017 and is headquartered in Rehovot, Israel. | Health Technology |
Amryt Pharma Plc
Amryt Pharma Plc Pharmaceuticals: MajorHealth Technology Amryt Pharma Plc operates as a holding company with interests in the development and delivery of treatments to help improve the lives of patients with rare and orphan diseases. The company was founded on July 17, 2019 and is headquartered in Dublin, Ireland. | Health Technology |
- Borsa valori
- Insiders
- Roni Mamluk